Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

ABSTRACT: The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

PROVIDER: PRJNA758288 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15652239.fastq.gz	Fastqsanger.gz
	SRR15652240.fastq.gz	Fastqsanger.gz
	SRR15652241.fastq.gz	Fastqsanger.gz
	SRR15652242.fastq.gz	Fastqsanger.gz
	SRR15652243.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer [ChIP-seq]

Project description:The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer [ChIP-seq]

| PRJNA762568 | ENA

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer [ChIP-seq]

Project description:To determine the functional epigenetic landscape of changes induced by H19, ChIP-seq was performed on H3K27me3 and H3K4me3 in V16D CRPC cells transduced with H19 (to induce NEtD) versus V16D CRPC control cells. Comaparison of genome-wide maps of chromatin state in V16D CRPC cells with and without H19 overexpression.

2021-09-15 | GSE183983 | GEO

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer

Project description:We report the effect of H19 knockdown on genome wide methylation by Enhanced Reduced Representation Bisulfite Sequencing (eRBBS) to detect quantitative base pair changes. Differential methylation genome wide analysis was done on NEPC derived organoid expressing shH19 or a control vector.

2021-09-12 | GSE182914 | GEO

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.

Project description: Not available

| S-EPMC8692330 | biostudies-literature

DPYSL5 is Highly Expressed in treatment-induced Neuroendocrine Prostate Cancer and Promotes Lineage Plasticity via EZH2/PRC2

Project description:Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a lethal subtype of castration-resistant prostate cancer resistant to androgen receptor (AR) inhibitors. Our study unveils that AR suppresses neuronal development protein dihydropyrimidinase-related protein 5 (DPYSL5), providing a mechanism for neuroendocrine transformation under androgen deprivation therapy. Our unique CRPC-NEPC cohort with 157 patient samples, including 55 t-NEPC patient samples, shows a high expression of DPYSL5 in t-NEPC patients, and that DPYSL5 correlates with neuroendocrine markers and inversely with AR and PSA. DPYSL5 overexpression in prostate cancer cells induces neuron like phenotype, enhances invasion, proliferation, and upregulates stemness and neuroendocrine related markers. Mechanistically, DPYSL5 promotes prostate cancer cell plasticity via EZH2-mediated PRC2 activation. Depletion of DPYSL5 halts proliferation, induces G1 phase cell cycle arrest, reverses neuroendocrine phenotype and upregulates luminal genes. In conclusion, DPYSL5 plays a critical role in regulating prostate cancer cell plasticity, and we propose the AR/DPYSL5/EZH2/PRC2 axis as a novel driver of t-NEPC progression.

2024-01-02 | GSE151433 | GEO

Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer

Project description:Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon associated with enhanced cell plasticity. Here, we show that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine transdifferentiation. In clinical prostate cancer samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with AR signalling. Over-expression of miR-194 facilitated the emergence of neuroendocrine features in prostate cancer cells, a process mediated by its ability to directly target a suite of genes involved in cell plasticity. One such target gene was FOXA1, which encodes a transcription factor with a vital role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor blocked epithelial-neuroendocrine transdifferentiation and inhibited the growth of cell lines and patient-derived organoids possessing neuroendocrine features. Overall, our study reveals a post-transcriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in NEPC.

2019-09-09 | GSE137071 | GEO

Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer

2019-09-09 | GSE137070 | GEO

Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer [ChIP-Seq]

2020-11-30 | GSE162319 | GEO

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer

Project description:Neuroendocrine prostate cancer (NEPC) is an aggressive and therapy-resistant subtype that emerges through lineage plasticity following inhibition of the androgen receptor (AR) signaling pathway. In this study, MYCL was overexpressed in prostate adenocarcinoma C4-2B cells and knocked down in neuroendocrine prostate cancer NCI-H660 cells to investigate its role in lineage regulation. RNA-sequencing analysis revealed that MYCL overexpression suppresses AR signaling and MYC target signaling while inducing neuroendocrine-like transcriptional reprogramming. In contrast, MYCL knockdown disrupts neuroendocrine lineage identity and restores adenocarcinoma-associated gene expression programs, including reactivation of MYC. These findings suggest that MYCL plays a key role in regulating lineage plasticity and maintaining neuroendocrine transcriptional programs in prostate cancer.

2026-05-12 | GSE324984 | GEO

MUC1-C Drives Lineage Plasticity in Progression to Neuroendocrine Prostate Cancer

Project description:MUC1-C Drives Lineage Plasticity in Progression to Neuroendocrine Prostate Cancer

| PRJNA579338 | ENA